Optimising Treatment in Isocitrate Dehydrogenase 1-Mutated Acute Myeloid Leukaemia and Beyond

This symposium and video were funded by Servier.

This symposium from European Hematology Association (EHA) Congress 2026, held between 11^th–14^th June, 2026, in Stockholm, Sweden, chaired by Gail Roboz, explored key topics: 

• Navigating treatment for patients with Isocitrate Dehydrogenase 1-Mutated (mIDH1) acute myeloid leukaemia (AML) ineligible for intensive chemotherapy 
• Clinical case spotlight: how to practically manage patients with mIDH1 AML ineligible for intensive chemotherapy
• What is on the horizon? Personalising treatment strategies for patients with AML eligible for intensive chemotherapy

Timestamps:

• 00:00:54 – Gail Roboz: Introduction and Opening Remarks  
• 00:06:18 – Agnieszka Wierzbowksa: Navigating Treatment for the Patient with mIDH1 AML Ineligible for Intensive Chemotherapy  
• 00:25:50 – Klaus Metzeler: Clinical Case Spotlight: How to Practically Manage the Patient with mIDH1 AML Ineligible for Intensive Chemotherapy  
• 00:47:17 – Vladimir Lazarevic: What is on the Horizon? Personalising Treatment Strategies for Patients with AML Eligible for Intensive Chemotherapy  
• 01:06:22 – Question and Answer Session

1. Director, Clinical & Translational Leukemia Programs, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA
2. Head of Department of Hematology, Faculty of Medicine, Medical University of Lodz, Poland
3. Department of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Germany
4. Senior Consultant, Department of Hematology, Oncology and Radiation Physics, Skånes University Hospital, Lund; Associate Professor, Lund University, Sweden

Roboz has served as a consultant for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses Pharma, Genoptix, GlaxoSmithKline, Geron, GlycoMimetics, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, MorphoSys, Neogenomics, Novartis, OncoPrecision, OncoVerity, Pfizer, Rigel, Roche, Syndax, and Servier; and has received research support from Janssen. 

Wierzbowska has received research grants from Jazz Pharmaceuticals; has received honoraria from AbbVie, Astellas, Bristol Myers Squibb (BMS)/Celgene, Genesis, Gilead/Kite, Janssen, Novartis, Pfizer, Servier, and Swixx Biopharma; and has participated on advisory boards for AbbVie, Astellas, Genesis, Gilead/Kite, Janssen, Novartis, Pfizer, and Servier. 

Metzeler has served as a consultant for AbbVie, Ascentage Pharma, BMS, Syndax; and received speakers’ honoraria from Servier, AbbVie, Astellas, AstraZeneca, BMS, Curis, Daiichi Sankyo, Janssen, Menarini, StemLine, Novartis, Pfizer, and Sysmex. 

Lazarevic has served on advisory boards for AbbVie, Astellas, Daiichi Sankyo, Servier, and Novartis.